MIRA Pharmaceuticals (NASDAQ:MIRA) Rating Lowered to “Sell” at Wall Street Zen

MIRA Pharmaceuticals (NASDAQ:MIRA) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Friday.

MIRA Pharmaceuticals Trading Up 1.4%

MIRA stock opened at $1.40 on Friday. The company has a market capitalization of $26.70 million, a P/E ratio of -2.86 and a beta of 1.75. MIRA Pharmaceuticals has a twelve month low of $0.73 and a twelve month high of $2.56. The business has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $1.24.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Research analysts predict that MIRA Pharmaceuticals will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of MIRA Pharmaceuticals during the second quarter worth $26,000. Creative Planning acquired a new stake in shares of MIRA Pharmaceuticals during the second quarter worth $27,000. Two Sigma Investments LP acquired a new stake in shares of MIRA Pharmaceuticals during the fourth quarter worth $28,000. Northern Trust Corp lifted its holdings in shares of MIRA Pharmaceuticals by 50.9% during the fourth quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after purchasing an additional 10,238 shares during the period. Finally, International Assets Investment Management LLC acquired a new stake in shares of MIRA Pharmaceuticals during the second quarter worth $42,000. 35.16% of the stock is owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.